nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—Fibromyalgia—Hydrochlorothiazide—nephrolithiasis	0.0472	0.0673	CcSEcCtD
Citalopram—Shoulder pain—Hydrochlorothiazide—nephrolithiasis	0.022	0.0313	CcSEcCtD
Citalopram—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.0203	0.0857	CbGpPWpGaD
Citalopram—Local swelling—Hydrochlorothiazide—nephrolithiasis	0.0169	0.0242	CcSEcCtD
Citalopram—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0183	CcSEcCtD
Citalopram—Trauma—Hydrochlorothiazide—nephrolithiasis	0.0124	0.0177	CcSEcCtD
Citalopram—Sinus bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0121	0.0172	CcSEcCtD
Citalopram—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0161	CcSEcCtD
Citalopram—ADRA1A—Endothelin Pathways—ADCY10—nephrolithiasis	0.0106	0.0449	CbGpPWpGaD
Citalopram—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0151	CcSEcCtD
Citalopram—Toothache—Hydrochlorothiazide—nephrolithiasis	0.00973	0.0139	CcSEcCtD
Citalopram—CYP2C19—urine—nephrolithiasis	0.00966	0.155	CbGeAlD
Citalopram—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.0086	0.0123	CcSEcCtD
Citalopram—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00821	0.0117	CcSEcCtD
Citalopram—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00799	0.0114	CcSEcCtD
Citalopram—CYP1A2—urine—nephrolithiasis	0.00789	0.127	CbGeAlD
Citalopram—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.00754	0.0108	CcSEcCtD
Citalopram—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00754	0.0108	CcSEcCtD
Citalopram—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00719	0.0103	CcSEcCtD
Citalopram—CYP2E1—urine—nephrolithiasis	0.0071	0.114	CbGeAlD
Citalopram—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.00669	0.00954	CcSEcCtD
Citalopram—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.0066	0.00941	CcSEcCtD
Citalopram—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00655	0.00934	CcSEcCtD
Citalopram—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00638	0.0091	CcSEcCtD
Citalopram—Gout—Hydrochlorothiazide—nephrolithiasis	0.00634	0.00904	CcSEcCtD
Citalopram—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00626	0.00892	CcSEcCtD
Citalopram—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00618	0.00881	CcSEcCtD
Citalopram—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00603	0.00859	CcSEcCtD
Citalopram—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00603	0.00859	CcSEcCtD
Citalopram—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00599	0.00854	CcSEcCtD
Citalopram—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00592	0.00844	CcSEcCtD
Citalopram—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00575	0.0082	CcSEcCtD
Citalopram—CYP3A4—urine—nephrolithiasis	0.00571	0.0917	CbGeAlD
Citalopram—CYP2D6—urine—nephrolithiasis	0.00562	0.0902	CbGeAlD
Citalopram—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00556	0.00792	CcSEcCtD
Citalopram—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00541	0.00771	CcSEcCtD
Citalopram—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00535	0.00763	CcSEcCtD
Citalopram—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00535	0.00763	CcSEcCtD
Citalopram—HTR2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00519	0.0219	CbGpPWpGaD
Citalopram—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00496	0.00708	CcSEcCtD
Citalopram—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00494	0.00704	CcSEcCtD
Citalopram—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00489	0.00698	CcSEcCtD
Citalopram—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00485	0.00691	CcSEcCtD
Citalopram—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.0048	0.00685	CcSEcCtD
Citalopram—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00476	0.00679	CcSEcCtD
Citalopram—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00471	0.00672	CcSEcCtD
Citalopram—Injury—Hydrochlorothiazide—nephrolithiasis	0.00467	0.00666	CcSEcCtD
Citalopram—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00463	0.00661	CcSEcCtD
Citalopram—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00459	0.00655	CcSEcCtD
Citalopram—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00457	0.00652	CcSEcCtD
Citalopram—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00455	0.00649	CcSEcCtD
Citalopram—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00453	0.0192	CbGpPWpGaD
Citalopram—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00453	0.00646	CcSEcCtD
Citalopram—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00453	0.00646	CcSEcCtD
Citalopram—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00451	0.00644	CcSEcCtD
Citalopram—HRH1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00449	0.019	CbGpPWpGaD
Citalopram—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00448	0.0189	CbGpPWpGaD
Citalopram—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00446	0.00636	CcSEcCtD
Citalopram—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00442	0.0063	CcSEcCtD
Citalopram—ADRA1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00441	0.0186	CbGpPWpGaD
Citalopram—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00436	0.0184	CbGpPWpGaD
Citalopram—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00431	0.00615	CcSEcCtD
Citalopram—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00429	0.00613	CcSEcCtD
Citalopram—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00429	0.00613	CcSEcCtD
Citalopram—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00426	0.00608	CcSEcCtD
Citalopram—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00423	0.00603	CcSEcCtD
Citalopram—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00423	0.00603	CcSEcCtD
Citalopram—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00422	0.0178	CbGpPWpGaD
Citalopram—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00415	0.00591	CcSEcCtD
Citalopram—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00407	0.0058	CcSEcCtD
Citalopram—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00404	0.00576	CcSEcCtD
Citalopram—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00402	0.017	CbGpPWpGaD
Citalopram—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00397	0.00566	CcSEcCtD
Citalopram—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00394	0.00562	CcSEcCtD
Citalopram—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00392	0.0056	CcSEcCtD
Citalopram—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00392	0.0056	CcSEcCtD
Citalopram—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00391	0.00558	CcSEcCtD
Citalopram—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00388	0.00554	CcSEcCtD
Citalopram—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00387	0.00552	CcSEcCtD
Citalopram—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00387	0.00552	CcSEcCtD
Citalopram—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00387	0.00552	CcSEcCtD
Citalopram—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00542	CcSEcCtD
Citalopram—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00379	0.0054	CcSEcCtD
Citalopram—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00379	0.0054	CcSEcCtD
Citalopram—HRH1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00378	0.016	CbGpPWpGaD
Citalopram—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00377	0.0159	CbGpPWpGaD
Citalopram—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00374	0.00533	CcSEcCtD
Citalopram—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00373	0.0158	CbGpPWpGaD
Citalopram—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00371	0.00529	CcSEcCtD
Citalopram—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00371	0.00529	CcSEcCtD
Citalopram—ADRA1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00371	0.0157	CbGpPWpGaD
Citalopram—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00364	0.00519	CcSEcCtD
Citalopram—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00362	0.00516	CcSEcCtD
Citalopram—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00353	0.0149	CbGpPWpGaD
Citalopram—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00347	0.00495	CcSEcCtD
Citalopram—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00345	0.00492	CcSEcCtD
Citalopram—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00343	0.00489	CcSEcCtD
Citalopram—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00342	0.00488	CcSEcCtD
Citalopram—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00339	0.00483	CcSEcCtD
Citalopram—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00338	0.00482	CcSEcCtD
Citalopram—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00335	0.00478	CcSEcCtD
Citalopram—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00333	0.00475	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00328	0.00468	CcSEcCtD
Citalopram—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00326	0.00465	CcSEcCtD
Citalopram—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00463	CcSEcCtD
Citalopram—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00463	CcSEcCtD
Citalopram—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00323	0.0046	CcSEcCtD
Citalopram—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00322	0.00459	CcSEcCtD
Citalopram—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00322	0.00459	CcSEcCtD
Citalopram—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00317	0.00453	CcSEcCtD
Citalopram—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00316	0.0045	CcSEcCtD
Citalopram—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00312	0.00445	CcSEcCtD
Citalopram—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00311	0.00443	CcSEcCtD
Citalopram—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00309	0.00441	CcSEcCtD
Citalopram—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00304	0.0128	CbGpPWpGaD
Citalopram—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00302	0.00431	CcSEcCtD
Citalopram—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00298	0.00425	CcSEcCtD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00297	0.0126	CbGpPWpGaD
Citalopram—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00424	CcSEcCtD
Citalopram—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00296	0.00422	CcSEcCtD
Citalopram—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00421	CcSEcCtD
Citalopram—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00293	0.00417	CcSEcCtD
Citalopram—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00408	CcSEcCtD
Citalopram—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00281	0.00401	CcSEcCtD
Citalopram—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00277	0.00395	CcSEcCtD
Citalopram—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00276	0.00393	CcSEcCtD
Citalopram—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00275	0.0116	CbGpPWpGaD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00272	0.0115	CbGpPWpGaD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00272	0.0115	CbGpPWpGaD
Citalopram—ADRA1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0027	0.0114	CbGpPWpGaD
Citalopram—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.00269	0.0114	CbGpPWpGaD
Citalopram—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00265	0.00379	CcSEcCtD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00263	0.0111	CbGpPWpGaD
Citalopram—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00263	0.00374	CcSEcCtD
Citalopram—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00259	0.00369	CcSEcCtD
Citalopram—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00364	CcSEcCtD
Citalopram—Tension—Hydrochlorothiazide—nephrolithiasis	0.00254	0.00362	CcSEcCtD
Citalopram—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00361	CcSEcCtD
Citalopram—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00358	CcSEcCtD
Citalopram—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00357	CcSEcCtD
Citalopram—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00249	0.00355	CcSEcCtD
Citalopram—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00348	CcSEcCtD
Citalopram—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00346	CcSEcCtD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00241	0.0102	CbGpPWpGaD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00241	0.0102	CbGpPWpGaD
Citalopram—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00342	CcSEcCtD
Citalopram—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00239	0.00341	CcSEcCtD
Citalopram—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00339	CcSEcCtD
Citalopram—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00236	0.00337	CcSEcCtD
Citalopram—ADRA1A—renal system—nephrolithiasis	0.00233	0.0375	CbGeAlD
Citalopram—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00233	0.00333	CcSEcCtD
Citalopram—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00331	CcSEcCtD
Citalopram—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00331	CcSEcCtD
Citalopram—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00232	0.0033	CcSEcCtD
Citalopram—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00326	CcSEcCtD
Citalopram—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00227	0.00324	CcSEcCtD
Citalopram—Cough—Hydrochlorothiazide—nephrolithiasis	0.00226	0.00322	CcSEcCtD
Citalopram—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00314	CcSEcCtD
Citalopram—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00314	CcSEcCtD
Citalopram—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00314	CcSEcCtD
Citalopram—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00313	CcSEcCtD
Citalopram—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00218	0.0031	CcSEcCtD
Citalopram—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00307	CcSEcCtD
Citalopram—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00213	0.00304	CcSEcCtD
Citalopram—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00211	0.00301	CcSEcCtD
Citalopram—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00211	0.00301	CcSEcCtD
Citalopram—Shock—Hydrochlorothiazide—nephrolithiasis	0.00208	0.00296	CcSEcCtD
Citalopram—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00207	0.00295	CcSEcCtD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00206	0.00871	CbGpPWpGaD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00206	0.00871	CbGpPWpGaD
Citalopram—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00206	0.00294	CcSEcCtD
Citalopram—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00204	0.00291	CcSEcCtD
Citalopram—CYP2B6—nephron tubule—nephrolithiasis	0.00204	0.0327	CbGeAlD
Citalopram—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00201	0.00287	CcSEcCtD
Citalopram—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00197	0.00281	CcSEcCtD
Citalopram—CYP1A2—renal system—nephrolithiasis	0.00193	0.031	CbGeAlD
Citalopram—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00192	0.00274	CcSEcCtD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00192	0.0081	CbGpPWpGaD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00192	0.0081	CbGpPWpGaD
Citalopram—CYP2E1—nephron tubule—nephrolithiasis	0.00191	0.0307	CbGeAlD
Citalopram—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00191	0.00272	CcSEcCtD
Citalopram—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.0019	0.0027	CcSEcCtD
Citalopram—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00188	0.00268	CcSEcCtD
Citalopram—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00188	0.00268	CcSEcCtD
Citalopram—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00186	0.00265	CcSEcCtD
Citalopram—CYP2B6—renal system—nephrolithiasis	0.00185	0.0297	CbGeAlD
Citalopram—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00184	0.00262	CcSEcCtD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00183	0.00771	CbGpPWpGaD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00183	0.00771	CbGpPWpGaD
Citalopram—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00182	0.0026	CcSEcCtD
Citalopram—Pain—Hydrochlorothiazide—nephrolithiasis	0.00181	0.00257	CcSEcCtD
Citalopram—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00181	0.00257	CcSEcCtD
Citalopram—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00179	0.00757	CbGpPWpGaD
Citalopram—CYP2B6—kidney—nephrolithiasis	0.00179	0.0287	CbGeAlD
Citalopram—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00248	CcSEcCtD
Citalopram—CYP2E1—renal system—nephrolithiasis	0.00174	0.0279	CbGeAlD
Citalopram—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00173	0.00246	CcSEcCtD
Citalopram—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00171	0.00722	CbGpPWpGaD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0017	0.00717	CbGpPWpGaD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0017	0.00717	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00169	0.00716	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00169	0.00716	CbGpPWpGaD
Citalopram—CYP2E1—kidney—nephrolithiasis	0.00168	0.0269	CbGeAlD
Citalopram—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00168	0.00239	CcSEcCtD
Citalopram—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00167	0.00238	CcSEcCtD
Citalopram—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00167	0.00238	CcSEcCtD
Citalopram—CYP2E1—cortex of kidney—nephrolithiasis	0.00163	0.0262	CbGeAlD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0016	0.00677	CbGpPWpGaD
Citalopram—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.0016	0.00677	CbGpPWpGaD
Citalopram—CYP2B6—Biological oxidations—SLC26A1—nephrolithiasis	0.00159	0.00673	CbGpPWpGaD
Citalopram—CYP2E1—Biological oxidations—SLC26A1—nephrolithiasis	0.00156	0.00659	CbGpPWpGaD
Citalopram—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00156	0.00222	CcSEcCtD
Citalopram—HRH1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00155	0.00656	CbGpPWpGaD
Citalopram—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00155	0.00654	CbGpPWpGaD
Citalopram—ADRA1A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00152	0.00644	CbGpPWpGaD
Citalopram—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00151	0.00216	CcSEcCtD
Citalopram—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00151	0.00639	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00151	0.00638	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0015	0.00634	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0015	0.00634	CbGpPWpGaD
Citalopram—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00149	0.00213	CcSEcCtD
Citalopram—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00144	0.00206	CcSEcCtD
Citalopram—CYP3A4—renal system—nephrolithiasis	0.0014	0.0224	CbGeAlD
Citalopram—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00199	CcSEcCtD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00139	0.00587	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00138	0.00585	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00138	0.00584	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00138	0.00584	CbGpPWpGaD
Citalopram—CYP2D6—renal system—nephrolithiasis	0.00137	0.0221	CbGeAlD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00136	0.00576	CbGpPWpGaD
Citalopram—CYP3A4—kidney—nephrolithiasis	0.00135	0.0217	CbGeAlD
Citalopram—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00134	0.00191	CcSEcCtD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00134	0.00567	CbGpPWpGaD
Citalopram—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00134	0.00567	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00134	0.00566	CbGpPWpGaD
Citalopram—Rash—Hydrochlorothiazide—nephrolithiasis	0.00133	0.0019	CcSEcCtD
Citalopram—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00133	0.0019	CcSEcCtD
Citalopram—CYP2D6—kidney—nephrolithiasis	0.00133	0.0213	CbGeAlD
Citalopram—Headache—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00189	CcSEcCtD
Citalopram—ADRA1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00132	0.00558	CbGpPWpGaD
Citalopram—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0013	0.00547	CbGpPWpGaD
Citalopram—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00179	CcSEcCtD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00122	0.00517	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00122	0.00517	CbGpPWpGaD
Citalopram—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.0012	0.00508	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00116	0.0049	CbGpPWpGaD
Citalopram—HRH1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00112	0.00474	CbGpPWpGaD
Citalopram—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00112	0.00473	CbGpPWpGaD
Citalopram—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00111	0.00468	CbGpPWpGaD
Citalopram—ADRA1A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0011	0.00465	CbGpPWpGaD
Citalopram—ABCB1—nephron tubule—nephrolithiasis	0.00109	0.0175	CbGeAlD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00105	0.00442	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00105	0.00442	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.001	0.00424	CbGpPWpGaD
Citalopram—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.001	0.00423	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.001	0.00423	CbGpPWpGaD
Citalopram—ABCB1—renal system—nephrolithiasis	0.000989	0.0159	CbGeAlD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000985	0.00416	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000973	0.00411	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000973	0.00411	CbGpPWpGaD
Citalopram—ABCB1—kidney—nephrolithiasis	0.000956	0.0153	CbGeAlD
Citalopram—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.000937	0.00396	CbGpPWpGaD
Citalopram—ABCB1—cortex of kidney—nephrolithiasis	0.000931	0.0149	CbGeAlD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000927	0.00392	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000927	0.00392	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000868	0.00367	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000868	0.00367	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000867	0.00367	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000865	0.00365	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000862	0.00364	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000862	0.00364	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000858	0.00362	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000851	0.0036	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000769	0.00325	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000769	0.00325	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.000756	0.00319	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000746	0.00315	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000746	0.00315	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000743	0.00314	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000741	0.00313	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000729	0.00308	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000723	0.00306	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000694	0.00293	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.000686	0.0029	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000665	0.00281	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000655	0.00277	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.000653	0.00276	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000653	0.00276	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000643	0.00272	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000614	0.0026	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000608	0.00257	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000608	0.00257	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.000597	0.00252	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—RGS14—nephrolithiasis	0.000595	0.00251	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.000593	0.00251	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—RGS14—nephrolithiasis	0.000584	0.00247	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000566	0.00239	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000564	0.00238	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000555	0.00235	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—PTH—nephrolithiasis	0.000518	0.00219	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.000516	0.00218	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.000511	0.00216	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—PTH—nephrolithiasis	0.000508	0.00215	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000477	0.00202	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000464	0.00196	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000461	0.00195	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000461	0.00195	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000442	0.00187	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000441	0.00186	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000434	0.00183	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000429	0.00181	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000429	0.00181	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ADCY10—nephrolithiasis	0.000413	0.00175	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	0.000412	0.00174	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.000405	0.00171	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ADCY10—nephrolithiasis	0.000405	0.00171	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DGKH—nephrolithiasis	0.000402	0.0017	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	0.0004	0.00169	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DGKH—nephrolithiasis	0.000394	0.00167	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000382	0.00161	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000382	0.00161	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000369	0.00156	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GRHPR—nephrolithiasis	0.000359	0.00152	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GRHPR—nephrolithiasis	0.000352	0.00149	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RGS14—nephrolithiasis	0.000351	0.00148	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	0.00035	0.00148	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RGS14—nephrolithiasis	0.000345	0.00146	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.000338	0.00143	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000335	0.00142	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AGXT—nephrolithiasis	0.00032	0.00135	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00032	0.00135	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000319	0.00135	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000314	0.00133	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AGXT—nephrolithiasis	0.000314	0.00133	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.000307	0.0013	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000305	0.00129	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PTH—nephrolithiasis	0.000293	0.00124	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	0.000292	0.00123	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00029	0.00123	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00029	0.00122	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PTH—nephrolithiasis	0.000287	0.00121	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000285	0.0012	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000274	0.00116	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.000274	0.00116	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—SLC26A1—nephrolithiasis	0.000272	0.00115	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—APRT—nephrolithiasis	0.000272	0.00115	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000271	0.00115	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—APRT—nephrolithiasis	0.000267	0.00113	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—SLC26A1—nephrolithiasis	0.000267	0.00113	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PTH—nephrolithiasis	0.000266	0.00112	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000265	0.00112	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	0.000265	0.00112	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PTH—nephrolithiasis	0.000261	0.0011	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.00025	0.00105	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000242	0.00102	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DGKH—nephrolithiasis	0.000237	0.001	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000237	0.001	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	0.000237	0.001	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000237	0.001	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000236	0.000998	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000233	0.000984	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DGKH—nephrolithiasis	0.000233	0.000984	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000222	0.00094	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000211	0.000894	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000206	0.000869	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000206	0.000869	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APRT—nephrolithiasis	0.000201	0.000848	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000201	0.000848	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000198	0.000837	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AQP1—nephrolithiasis	0.000194	0.00082	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AQP1—nephrolithiasis	0.00019	0.000803	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000189	0.000799	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000189	0.000799	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AGXT—nephrolithiasis	0.000188	0.000797	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000181	0.000765	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CHRM3—nephrolithiasis	0.000175	0.000741	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CHRM3—nephrolithiasis	0.000172	0.000726	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CHRM3—nephrolithiasis	0.000172	0.000725	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	0.000171	0.000723	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000168	0.000712	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000163	0.00069	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	0.00016	0.000677	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APRT—nephrolithiasis	0.00016	0.000677	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTH—nephrolithiasis	0.000157	0.000663	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTH—nephrolithiasis	0.000156	0.000661	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTH—nephrolithiasis	0.000154	0.000651	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000147	0.000619	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000145	0.000615	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AQP1—nephrolithiasis	0.000143	0.000605	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000135	0.00057	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000133	0.00056	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CHRM3—nephrolithiasis	0.000129	0.000547	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000124	0.000523	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000124	0.000523	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000122	0.000515	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AQP1—nephrolithiasis	0.000114	0.000483	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CHRM3—nephrolithiasis	0.000103	0.000436	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	9.09e-05	0.000384	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AQP1—nephrolithiasis	8.81e-05	0.000372	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CHRM3—nephrolithiasis	7.97e-05	0.000337	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SPP1—nephrolithiasis	7.88e-05	0.000333	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	7.85e-05	0.000332	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SPP1—nephrolithiasis	7.73e-05	0.000327	CbGpPWpGaD
